How to Add NAD+ Therapy to a Med Spa: 2026 Guide

Adding NAD+ therapy to a med spa requires more than purchasing a product and training staff. The practice needs a licensed clinician to evaluate and order treatment, a state-compliant prescribing and administration workflow, documented pharmacy controls, informed consent, adverse-event procedures, and advertising that does not present NAD+ as FDA-approved or proven for unsupported wellness claims.

Is NAD+ FDA-approved for a med spa program?

No NAD+ product is identified in the reviewed FDA sources as FDA-approved for anti-aging, energy, cognitive, detoxification, or general wellness use. Injectable NAD+ offered by a clinic is a compounded preparation when it is prepared through a compounding pathway; it should not be described as an FDA-approved therapy.

That distinction affects nearly every part of a NAD+ therapy business: product sourcing, consent, clinical review, website language, staff training, and records. A clinic should describe the service conservatively as a clinician-evaluated NAD+ service using a prescription or compounded product where legally available. The exact product, formulation, route, and intended use still require review by the responsible clinician and pharmacy.

FDA has also warned that food-grade NAD+ or repackaged dietary-ingredient material is not suitable for sterile injectable compounding without appropriate processing. The agency reported adverse-event complaints involving NAD+ injectable drugs, including severe chills, shaking, vomiting, and fatigue; some patients required medical treatment. Those warnings make pharmacy documentation a launch requirement, not a purchasing detail.

What does a clinic need before it can offer NAD+?

A clinic needs a defined clinical owner, lawful prescribing authority, a pharmacy relationship, an administration workflow, consent materials, and state-specific business and facility review before marketing the service.

The core setup can be organized into five workstreams:

An owner should also decide whether the program is in-person, telehealth-supported, or hybrid. A remote visit does not remove the need to comply with the law of the state where the patient is located, the clinician’s scope of practice, the standard of care, or informed-consent requirements.

For owners comparing operational models, the telehealth programs hub provides context on how branded clinical programs can be structured. MDLaunchr is one infrastructure option in this category: the platform supports the business workflow, while independently licensed clinicians make clinical decisions. It does not replace state-specific clinical governance or pharmacy review.

Who evaluates and orders NAD+ for a medical practice?

An authorized, state-licensed clinician must evaluate the patient and determine whether an NAD+ product is medically appropriate; a nonclinical owner, front-desk employee, or marketing company cannot make that decision.

A defensible evaluation and ordering workflow should address, as applicable:

• Relevant medical history and current medications.
• Allergies and clinically relevant risks.
• The patient’s stated goal and the clinician’s documented rationale.
• The exact product and formulation under consideration.
• The route of administration and location of administration.
• Informed consent and alternatives.
• Follow-up, escalation, and adverse-event documentation.

The reviewed federal sources do not establish one national NAD+ medical-director rule. Instead, the responsible clinician, ownership model, supervision arrangement, and administration workflow depend heavily on state law. The practice should identify who evaluates, who orders, who administers, who supervises, and who handles follow-up before the first appointment is scheduled.

A “medical director on paper” is not a substitute for actual clinical responsibility. The clinical leader should approve protocols, competency requirements, documentation standards, product controls, and quality-review procedures within the limits of applicable law.

Where can clinics source compounded NAD+?

A clinic should source NAD+ only after reviewing the pharmacy’s compounding category, licenses, ingredient documentation, sterile controls, labeling, and federal legal basis for the specific product.

FDA explains that compounded drugs may be prepared by a licensed pharmacist in a state-licensed pharmacy, by a physician, or by or under the direct supervision of a licensed pharmacist in an outsourcing facility. The requirements differ depending on whether the product is prepared under section 503A or 503B.

Before contracting with a pharmacy, request and retain documentation addressing:

1. 1Whether the pharmacy is a 503A patient-specific compounding pharmacy or a 503B outsourcing facility.
2. 2State pharmacy licenses and FDA registration status where applicable.
3. 3The exact source and grade of the NAD+ ingredient.
4. 4Sterility controls, testing, and quality documentation.
5. 5Product labeling, lot information, expiration or beyond-use date, and shipping conditions.
6. 6Recall, complaint, and adverse-event procedures.
7. 7Whether the product ships to the patient or the clinic.
8. 8The pharmacy’s written legal basis for compounding the specific NAD+ preparation.

Do not rely on a pharmacy’s advertising statement that “NAD+ is available.” FDA’s January 20, 2026 warning letter to GenoGenix LLC stated that the cited NAD+ products were not eligible for the section 503B exemptions because NAD+ was not on the applicable 503B bulk-drug list and was not being used to compound a drug on the FDA drug-shortage list. That action concerned the cited facility; it is not a complete nationwide legal opinion. It is nevertheless an important sourcing-risk signal.

The shortage-list issue also requires care. FDA explains that certain restrictions can change when an FDA-approved drug appears on the FDA drug-shortage list, but a shortage theory does not automatically make every compounded product lawful. A clinic should verify the current list and obtain pharmacy-specific documentation rather than assume that NAD+ qualifies.

For broader background on how compounding questions affect clinic operations, review the FDA peptide compounding rules for telehealth clinics. The substances differ, but the operational lesson is similar: identify the compounder, pathway, ingredient, documentation, and applicable restrictions.

What room and staffing requirements apply?

There is no single national room or staffing standard for every NAD+ program. Requirements can depend on the state, the administration route, the facility type, the personnel involved, and whether the service includes IV therapy.

Before opening bookings, ask the relevant state and facility regulators or qualified counsel to review:

• Whether the location needs a medical-facility, clinic, office-based surgery, or other license.
• Whether IV administration triggers additional facility or emergency-equipment requirements.
• Which personnel may start an IV, administer medication, monitor a patient, and respond to an adverse event.
• Whether a supervising physician must be physically present or available remotely.
• What emergency supplies and transfer procedures are required.
• How competency checks and quality reviews will be documented.
• Whether the pharmacy may ship the product to the clinic.

This is one area where copying another med spa’s setup can create risk. A room that appears adequate for one state, route, or staffing model may not satisfy another jurisdiction’s requirements.

California, Texas, and New York illustrate the differences

In California, the Medical Board states that nonphysicians may not control clinical decisions and identifies patient evaluation, diagnosis, treatment options, medical-record control, clinical hiring, and selection of medical equipment or supplies as decisions that must remain under physician control. California also treats telehealth as a tool for practicing medicine rather than a separate form of medicine, applies the same standard of care as in-person care, and requires telehealth-consent documentation. A California med spa should review its ownership and professional-entity structure before adding NAD+.

In Texas, physician delegation is permitted for certain medical acts when the person is qualified and properly trained, the act can be safely performed, and supervision requirements are met. The delegating physician remains responsible for delegated medical acts. Texas prescriptive-authority delegation to an APRN or PA requires an appropriate agreement, registration, and supervision. Texas Medical Board guidance also identifies cosmetic medication injections and elective IV therapy as medical-practice activities. A Texas NAD+ injection program therefore needs real supervision, documented authority, trained personnel, and compliant orders or protocols.

In New York, Department of Health guidance describes corporate-practice restrictions that generally prevent an unauthorized corporation from providing or arranging professional services unless an authorized structure applies. A New York practice should examine ownership, management agreements, marketing, and clinician contracting rather than assume that a general business corporation can operate and advertise the medical service.

These are examples, not a national rule. Ownership, delegation, supervision, telehealth, and facility requirements vary by state and may also depend on the patient’s location.

What should NAD+ consent explain?

Consent should clearly explain that NAD+ is not FDA-approved for the promoted wellness purposes and that evidence and regulatory status can vary by formulation, route, product, and indication.

A clinic’s consent materials should identify:

• What NAD+ is and what specific product will be used.
• Whether the product is compounded and, if so, the relevant status disclosed by the pharmacy.
• That the product is not FDA-approved for the promoted wellness purpose.
• Known and uncertain benefits without promising an outcome.
• Material risks and possible adverse reactions.
• Alternatives, including no treatment and conventional care where relevant.
• The possibility that evidence is limited or not established for the patient’s goal.
• Who evaluates and orders the service.
• Who administers it and under whose authority or supervision.
• How follow-up, complaints, and adverse events will be handled.

The consent form should not be used as a workaround for unsupported marketing. A disclaimer does not cure a website that otherwise creates the impression that NAD+ reverses aging, repairs mitochondria, treats addiction, prevents dementia, detoxifies the body, or reliably increases energy.

How can a med spa describe NAD+ without making risky claims?

A clinic should use factual descriptions of the service and avoid presenting unsupported outcomes as established effects. FTC guidance requires health-related advertising to be truthful, not misleading, and supported by adequate substantiation before dissemination. The overall net impression matters, including testimonials, images, product names, charts, and clinician endorsements.

Lower-risk descriptions may include:

• “Clinician-evaluated NAD+ service.”
• “NAD+ therapy using a prescription or compounded product, where legally available.”
• “Discuss whether NAD+ treatment is appropriate for your goals and medical history.”
• “Evidence and regulatory status vary by formulation, route, and indication.”

High-risk claims include “FDA-approved NAD+ therapy,” “reverses aging,” “repairs mitochondria,” “detoxifies the body,” “treats addiction,” “prevents dementia,” and “clinically proven to increase energy.” A claim that a service is clinically proven or supported by studies should be tied to evidence matching the actual product, route, population, and outcome. Testimonials alone do not substantiate objective health claims.

The same principle applies to an NAD+ injection program for clinics: the program page, intake flow, consent materials, email campaigns, and social posts should all describe the service consistently.

What is the safest setup sequence for an NAD+ program?

Use this sequence to keep the business, clinical, pharmacy, and advertising decisions connected:

1. 1Define the service. Decide whether the program is in-person, telehealth-supported, or hybrid; identify the intended use and administration route.
2. 2Map state requirements. Review ownership, clinician licensure, scope, delegation, supervision, telehealth, facility, and administration rules for each launch state.
3. 3Assign clinical responsibility. Identify the clinician responsible for evaluation, ordering, consent, follow-up, escalation, and quality review.
4. 4Vet the pharmacy. Confirm 503A or 503B status, licenses, ingredient source, sterility controls, labeling, shipping, records, and legal basis.
5. 5Build the record. Create evaluation, order, administration, lot, adverse-event, follow-up, and recall documentation.
6. 6Prepare the facility and team. Confirm permitted personnel, training, emergency supplies, monitoring, transfer procedures, and supervision availability.
7. 7Write consent and advertising. Explain non-FDA-approved status for the promoted purpose, uncertainties, risks, alternatives, and responsible clinicians; remove unsupported claims.
8. 8Run a limited operational review. Test intake, clinician review, pharmacy communication, administration records, follow-up, complaints, and escalation before broad promotion.

Before launch, have a qualified healthcare attorney review the entity, ownership, pharmacy, delegation, telehealth, and advertising structure, and have the responsible clinician review the clinical workflow and consent materials. This article is educational and does not replace legal or medical advice.

Can a white-label platform support a NAD+ business?

A white-label telehealth platform can provide infrastructure for branding, intake, workflow, communications, and program operations, but it cannot make an otherwise noncompliant NAD+ service lawful. The clinic remains responsible for choosing a permissible business structure, using an appropriate pharmacy, complying with state requirements, and ensuring that clinical decisions remain with independently licensed clinicians.

MDLaunchr supports white-label telehealth programs under the clinic’s brand; its role is operational infrastructure rather than prescribing, compounding, pharmacy ownership, or regulatory approval. Owners should compare any platform against their own requirements for clinician governance, patient-location controls, documentation, pharmacy workflow, consent, and advertising review.

If the operating model fits your practice, see the white-label NAD+ longevity program to review how the program is set up.

Related reading: Cost to Start a Peptide Therapy Business (2026).